Drugs / NIO752
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06372821 | Nov 2024 → Jul 2026 overdue | Alzheimer disease | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT05469360 | Feb 2023 → Jul 2026 overdue | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04539041 | Feb 2021 → Oct 2024 | progressive supranuclear palsy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07498426 | Jun 2026 → Jul 2029 expected | supranuclear palsy, progressive, 1 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIO752 | “4 injections of NIO752 at dose A” NCT04539041 ↗ |
| Action | Inhibit | “It is thought that NIO752 reduces production of tau.” NCT06372821 ↗ |
| Modality | Antisense oligonucleotide | “solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels” NCT04539041 ↗ |
| Route | Intrathecal | “injected intrathecally (spine tap)” NCT04539041 ↗ |